SCHEMBL20178581

SCHEMBL20178581

CCCCCCC(C)c1ccc(C(=O)OC)c(C(F)(F)F)c1

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
THRA P10827 1/20 0.41
THRB P10828 1/20 0.41
PTGS2 P35354 1/20 0.40
CFTR P13569 2/20 0.39
ALDH1A1 P00352 2/20 0.38
MLYCD O95822 1/20 0.37
KDM4E B2RXH2 1/20 0.36
HPGD P15428 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
CNR1 P21554 1/20 0.36
CNR2 P34972 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2C9 P11712 1/20 0.36
MAPK1 P28482 1/20 0.36
CYP2C19 P33261 1/20 0.36
NOTUM Q6P988 1/20 0.36
S1PR1 P21453 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20178578 0.88 ALDH1A1 (0.43) THRATHRBPTGS2ALDH1A1MLYCD
SCHEMBL20178592 0.81 CFTR (0.43) CFTRALDH1A1KDM4ENOTUM
SCHEMBL20173743 0.79 CFTR (0.48) CFTRALDH1A1KDM4EHPGDNOTUM
SCHEMBL21466515 0.77 UBE2M (0.38) PTGS2CNR2
SCHEMBL22358717 0.76 SMN1; SMN2 (0.43) ALDH1A1KDM4EHPGDTDP1MAPK1
SCHEMBL20154440 0.76 SLC6A3 (0.40) S1PR1
SCHEMBL16726459 0.75 THRA (0.60) THRATHRBCFTRALDH1A1KDM4E
SCHEMBL20178593 0.75 PPARA (0.46) THRATHRBCFTRALDH1A1KDM4E
SCHEMBL22561848 0.74 RORC (0.38) PTGS2MLYCDCNR1CNR2NOTUM
SCHEMBL14640215 0.74 MGLL (0.49) ALDH1A1TDP1CYP3A4CYP2C9MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10597391-B2 Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof ENANTA PHARMACEUTICALS, INC. (US) 2020-03-24 US disclosed
US-20180141941-A1 UREA-CONTAINING ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF ENANTA PHARMACEUTICALS, INC. 2018-05-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180141941-A1 UREA-CONTAINING ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF NR1H4, FXR1, SLC10A1 THRA 468/4885THRB 461/4885PTGS2 1196/4885
US-10597391-B2 Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof NR1H4, FXR1, SLC10A1 THRA 468/4885THRB 461/4885PTGS2 1196/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.